REVIVA PHARMACEUTICALS HOLDINGS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that REVIVA PHARMACEUTICALS HOLDINGS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($4.01M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($6.05M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($6.43M) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($8.37M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($7.86M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($7.43M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($11.35M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($11.71M) | Aug 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($6.85M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($3.52M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($5.34M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($7.37M) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($2.28M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($1.61M) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($949.3K) | May 16, 2022 |
| Q3 | 2020 | Nov 30, 2020 | ($348.2K) | Jan 14, 2021 |
| Q3 | 2021 | Sep 30, 2020 | ($659.1K) | Nov 15, 2021 |
| Q2 | 2020 | Aug 31, 2020 | ($516.0K) | Oct 14, 2020 |
| Q3 | 2020 | Aug 31, 2020 | ($516.0K) | Jan 14, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($851.4K) | Aug 16, 2021 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($4.03M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($6.07M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($6.54M) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($8.46M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($8.13M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($7.92M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($11.56M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($11.34M) | Aug 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($6.98M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($3.56M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($5.52M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($7.45M) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($2.48M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($1.79M) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($1.87M) | May 16, 2022 |
| Q3 | 2020 | Nov 30, 2020 | ($352.0K) | Jan 14, 2021 |
| Q3 | 2021 | Sep 30, 2020 | ($512.3K) | Nov 15, 2021 |
| Q2 | 2020 | Aug 31, 2020 | ($525.9K) | Oct 14, 2020 |
| Q2 | 2021 | Jun 30, 2020 | ($777.4K) | Aug 16, 2021 |
| Q1 | 2020 | May 31, 2020 | ($264.9K) | Jul 7, 2020 |